Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06362252 · ClinicalTrials.gov registry record · Phase 1

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

A Phase 1 study of Extensive-stage Small-cell Lung Cancer, sponsored by Daiichi Sankyo.

Recruiting
Registry status
Phase 1
Development phase
123
Enrollment target
20
Study locations

NCT06362252: Recruiting Phase 1 study of Extensive-stage Small-cell Lung Cancer, sponsored by Daiichi Sankyo.

NCT06362252 is a Phase 1 study of Extensive-stage Small-cell Lung Cancer that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 123 participants, below the 171-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06362252, a Phase 1 study of Extensive-stage Small-cell Lung Cancer, is actively recruiting participants, sponsored by Daiichi Sankyo.

RECRUITING
Registry status
Phase 1
Development phase
123 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.

Conditions Studied

Extensive-stage Small-cell Lung Cancer

Interventions

  • DRUG Carboplatin
  • DRUG Atezolizumab
  • DRUG Ifinatamab deruxtecan

Study Locations (20)

New York

  • New York University Cancer Center - Laura and Isaac Perlmutter Cancer Center At Nyu Langone - Mineola
  • NYU Langone Hospital - Long Island - Mineola
  • Memorial Sloan Kettering Cancer Center - New York
  • Columbia University Hervert Irving Comprehensive Cancer Center - New York
  • Montefiore Medical Center - New York

Florida

  • Mayo Clinic-Jacksonville - Jacksonville
  • Advent Health Orlando - Orlando
  • Moffitt Cancer Center - Tampa

California

  • David Geffen School of Medicine - Los Angeles
  • Hoag Memorial Hospital Presbyterian - Newport Beach

Minnesota

  • Regents of the University of Minnesota - Minneapolis
  • Mayo Clinic - Rochester

New Jersey

  • Astera Cancer Care - East Brunswick
  • John Theurer Cancer Center At Hackensack Umc - Hackensack

Alabama

  • University of Alabama -Birmingham - Birmingham

Arizona

  • Mayo Clinic Arizona - Phoenix

Illinois

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2024-07-22
Est. Completion 2026-12-30
Phase Phase 1
Daiichi Sankyo

236 total trials

What NCT06362252 shows while recruiting

NCT06362252 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, below the 171-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (28% lower).

The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.

NCT06362252 names 20 study sites across 11 states, led by New York, Florida, California.

Frequently Asked Questions

What is clinical trial NCT06362252 about?

NCT06362252 is a clinical study titled "A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)". This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung cancer (ES-SCLC) in the first-line (1L) setting.

What is the current status of trial NCT06362252?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 123 participants. The study started on 2024-07-22. Estimated completion is 2026-12-30.

What conditions does trial NCT06362252 study?

This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.

What interventions are being tested in trial NCT06362252?

The interventions under investigation include: Carboplatin (DRUG), Atezolizumab (DRUG), Ifinatamab deruxtecan (DRUG).

Who is sponsoring clinical trial NCT06362252?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06362252 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Extensive-stage Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06362252's enrollment target sits among peer trials

123 12th of 25 higher than 14 of 25 other Extensive-stage Small-cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Extensive-stage Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05285891 · 123 participants · Phase 4

    Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

  • NCT05334368 · 123 participants · Phase 3

    Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

  • NCT06088355 · 123 participants · NA

    Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease

  • NCT06111131 · 123 participants · NA

    Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06362252

Source: ClinicalTrials.gov NCT06362252, the US trial registry maintained by the National Library of Medicine. NCT06362252 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.